ARA-290 (Cibinetide)
cibinetidearieta-2
Tissue-protective peptide developed for small-fiber neuropathy. Pain + inflammation tracking.
- Half-life
- 2 h
- Out of system
- ~10 h
- Route
- Subcutaneous
- Level
- Advanced
Short-acting — protocols usually dose daily. After the last dose, roughly 97% has cleared in ~10 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What ARA-290 (Cibinetide) is used for
- Tissue-protective peptide developed for small-fiber neuropathy
- Reported pain and inflammation reduction
How it's typically used
Trial range: ~4 mg subcutaneous daily.
What to watch for
- Still investigational; trial-stage evidence
- No established consumer protocol
- Research-only outside trials
About Other research compounds
- What they are
- Nootropics, metabolic agents, and research compounds that don't fit the other classes.
- How they're run
- Route and schedule vary widely — check the individual entry.
- What to watch
- This is the least-characterised corner of the atlas. Read the full guide, and treat anything without published human data as exactly that.
Full guide
ARA-290 (Cibinetide): A Tracking Guide for Tissue Protection and Neuropathic Pain
What ARA-290 is, why it was developed for small-fiber neuropathy, and how to track pain, sensation, and inflammatory markers if you use it.
Other other research compounds
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.